X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215647
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-01-2022-1654158193.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-november-17-2021-1637135168.pdf
https://www.prnewswire.com/news-releases/emmaus-life-sciences-announces-partnership-with-upscript-to-provide-telehealth-solutions-to-sickle-cell-disease-patients-301422030.html
https://www.biospace.com/article/releases/emmaus-life-sciences-reinforces-positive-outcomes-of-endari-clinical-trials-including-efficacy-findings-that-led-to-fda-approval/?s=95
https://www.prnewswire.com/news-releases/emmaus-life-sciences-announces-withdrawal-of-marketing-authorization-application-to-european-medicines-agency-300922039.html
https://endpts.com/ema-and-fda-historically-agree-on-just-about-every-new-drug-approval-but-is-that-slowly-changing/?utm_medium=email&utm_campaign=791%20Monday%20August%2019%20-%20Can%20controversial%20Sarepta%20scoop%20up%20another%20early%20OK%20for%20Duchenne%20MD%20This%20biotech%20raised%20100M%20for%20anti-aging%20RD&utm_content=791%20Monday%20August%2019%20-%20Can%20controversial%20Sarepta%20scoop%20up%20another%20early%20OK%20for%20Duchenne%20MD%20This%20biotech%20raised%20100M%20for%20anti-aging%20RD+CID_09c67b5e3f4fc4197c71932073266fc7&utm_source=ENDPOINTS%20emails&utm_term=EMA%20and%20FDA%20historically%20agree%20on%20just%20about%20every%20new%20drug%20approval%20but%20is%20that%20slowly%20changing
https://www.raps.org/news-and-articles/news-articles/2019/8/ema-and-fda-historically-agree-on-just-about-every
http://www.pharmatimes.com/news/az_bags_two_extensions_in_latest_chmp_decisions_1292946
https://www.raps.org/news-and-articles/news-articles/2019/6/emas-chmp-rejects-another-drug-approved-by-us-fda
https://www.raps.org/news-and-articles/news-articles/2019/5/emas-chmp-offers-negative-opinion-for-sickle-cell
https://www.raps.org/news-and-articles/news-articles/2019/5/emas-chmp-offers-negative-opinion-for-sickle-cell
https://www.pharmacompass.com/pdf/news/Enforcement-Report-Week-of-November-7-2018-1541578996.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-17-2018-1516166737.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-18-2017-1508294527.pdf
https://www.pharmacompass.com/pdf/news/Bella-Pharmaceuticals-Inc-Issues-Voluntary-Nationwide-Recall-of-All-Sterile-Drug-Products-1503117778.pdf
http://raps.org/Regulatory-Focus/News/2017/07/07/28055/FDA-Approves-First-New-Sickle-Cell-Drug-in-Almost-20-Years/?utm_source=Email&utm_medium=Informz&utm_campaign=Informz-Emails
http://www.prnewswire.com/news-releases/emmaus-life-sciences-inc-receives-notice-of-allowance-for-japanese-patent-for-use-of-l-glutamine-in-treatment-of-diabetes-300401750.html
http://newatlas.com/drug-cancels-cancer-backup-plans/47556/
http://www.prnewswire.com/news-releases/emmaus-life-sciences-inc-receives-japanese-patent-for-use-of-l-glutamine-in-treatment-of-diverticulosis-300376733.html
http://www.prnewswire.com/news-releases/emmaus-new-drug-application-for-sickle-cell-disease-accepted-for-review-by-fda-300358916.html
Market Place
Share 
